NASDAQ:ADIL - Adial Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 727.07 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.33
▲ +0.02 (1.53%)

This chart shows the closing price for ADIL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adial Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADIL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADIL

Analyst Price Target is $11.00
▲ +727.07% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Adial Pharmaceuticals in the last 3 months. The average price target is $11.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 727.07% upside from the last price of $1.33.

This chart shows the closing price for ADIL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Adial Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/30/2021Litchfield Hills ResearchReiterated RatingBuyLow
10/13/2021Brookline Capital AcquisitionInitiated CoverageBuy$12.00High
10/13/2021Brookline Capital ManagementReiterated RatingBuy$12.00High
8/26/2021Litchfield Hills ResearchBoost Price TargetBuy$5.00 ➝ $15.00High
8/20/2021Maxim GroupReiterated RatingBuy$5.00Medium
6/29/2021Litchfield Hills ResearchInitiated CoverageBuy$5.00Low
6/7/2019Maxim GroupSet Price TargetBuy$5.00Medium
4/12/2019Dawson JamesReiterated RatingBuyMedium
3/26/2019Maxim GroupSet Price TargetBuy$5.00Low
12/13/2018Maxim GroupReiterated RatingBuy$5.00High
11/14/2018Maxim GroupReiterated RatingBuy$5.00Low
10/30/2018Maxim GroupInitiated CoverageBuy ➝ Buy$5.00Low
10/11/2018Dawson JamesInitiated CoverageBuyHigh
10/1/2018Dawson JamesReiterated RatingBuyLow
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/27/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/26/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/25/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/24/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/25/2022

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Adial Pharmaceuticals logo
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Read More

Today's Range

Now: $1.33
Low: $1.25
High: $1.35

50 Day Range

MA: $1.66
Low: $1.19
High: $2.13

52 Week Range

Now: $1.33
Low: $1.14
High: $5.08

Volume

37,887 shs

Average Volume

116,405 shs

Market Capitalization

$31.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Adial Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Adial Pharmaceuticals in the last twelve months: Brookline Capital Acquisition Corp., Brookline Capital Management, Litchfield Hills Research, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for ADIL.

What is the current price target for Adial Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Adial Pharmaceuticals in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 727.1%.
View the latest price targets for ADIL.

What is the current consensus analyst rating for Adial Pharmaceuticals?

Adial Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADIL will outperform the market and that investors should add to their positions of Adial Pharmaceuticals.
View the latest ratings for ADIL.

How do I contact Adial Pharmaceuticals' investor relations team?

Adial Pharmaceuticals' physical mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company's listed phone number is (434) 422-9800 and its investor relations email address is [email protected] The official website for Adial Pharmaceuticals is www.adialpharma.com. Learn More about contacing Adial Pharmaceuticals investor relations.